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Abstract
Glioblastoma (GB) is a highly invasive and lethal brain tumor due to its universal recurrence. Although it has been suggested
that the electroneutral Na
+-K
+-Cl
2 cotransporter 1 (NKCC1) can play a role in glioma cell migration, the precise mechanism
by which this ion transporter contributes to GB aggressiveness remains poorly understood. Here, we focused on the role of
NKCC1 in the invasion of human primary glioma cells in vitro and in vivo. NKCC1 expression levels were significantly higher
in GB and anaplastic astrocytoma tissues than in grade II glioma and normal cortex. Pharmacological inhibition and shRNA-
mediated knockdown of NKCC1 expression led to decreased cell migration and invasion in vitro and in vivo. Surprisingly,
knockdown of NKCC1 in glioma cells resulted in the formation of significantly larger focal adhesions and cell traction forces
that were approximately 40% lower than control cells. Epidermal growth factor (EGF), which promotes migration of glioma
cells, increased the phosphorylation of NKCC1 through a PI3K-dependant mechanism. This finding is potentially related to
WNK kinases. Taken together, our findings suggest that NKCC1 modulates migration of glioma cells by two distinct
mechanisms: (1) through the regulation of focal adhesion dynamics and cell contractility and (2) through regulation of cell
volume through ion transport. Due to the ubiquitous expression of NKCC1 in mammalian tissues, its regulation by WNK
kinases may serve as new therapeutic targets for GB aggressiveness and can be exploited by other highly invasive
neoplasms.
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Introduction
Glioblastoma (GB) is the most common malignant primary
brain tumor. GBs are aggressive and display key features of
invasion and infiltration of healthy brain tissue [1]. Due to its
invasive nature, GB is not curable through surgical resection [2,3].
The surgical and medical treatment for patients with this disease
has evolved in the last 20 years, however the prognosis remains
dismal due to tumor recurrence [4]. Thus, understanding the
mechanisms that GB cells utilize during migration and invasion
into normal brain tissue is paramount in the development of novel,
effective therapies.
Volume regulation, cytoskeletal rearrangements, and adhesion
dynamics are major determinants of cell migration and are essential
processes in invasion [5,6]. Migration of mammalian cells is
accompanied by volume changes. For instance, neutrophils [7] and
dendritic cells [8] undergo cell volume increases when exposed to
signals leading to migratory responses. Indeed, it has been hy-
pothesized that inhibition of cell volume regulation impairs cell
migration [9,10]. NKCC1, a transporter that belongs to the
SLC12A family of cation-chloride cotransporters, is a fundamental
transporter utilized in the regulation of intracellular volume and in
the accumulation of intracellular Cl
2 [11,12]. NKCC1 mediates
the movement of Na
+,K
+, and Cl
2 ions across the plasma
membrane using the energy stored in the Na
+ gradient, generated
by the Na
+/K
+ ATPase. Recent work supports the notion that
intracellular volume regulation by NKCC1 [13,14], as well as
aquaporin4(AQP4) [15],mayindeedpromoteglioma cellinvasion.
However, whether cell volume regulation is the only or primary
mechanism mediating NKCC1 effects is unclear. It is equally
unclear if NKCC1 is differentially regulated in invasive cells.
In addition to cell volume regulation, ion transporters can
participate in anchoring the cytoskeleton to the plasma membrane
by binding to ezrin-radixin-moesin (ERM) proteins [16,17]. ERM
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proteins, which connect the cytoskeleton to the plasma membrane
[18]. Anion exchangers (AE) 1, 2, and 3, Na
+/H
+ exchanger 1
(NHE1), and a Na
+/Ca
++ exchanger are all able to act as
cytoskeletal anchors by interacting with ERM proteins [19]. It has
been shown that ERM proteins bind to clusters of positive amino
acids in the juxtamembranous domain of NHE1, CD44, CD43,
and ICAM-2 [16,20] and that these interactions regulate cell
migration and contractility, as well as focal adhesion turnover
[21,22]. The interaction between ion transporters, as integral
membrane proteins, and the cytoskeleton mediates the transduc-
tion of contractile forces generated from within the cell to the
extracellular matrix and promotes migration. However, the mech-
anistic action of NKCC1 on cell contractility and focal adhesion
dynamics in the context of GB cell migration and invasion are
entirely unknown.
Activation of NKCC1 transport activity requires phosphoryla-
tion of key threonine residues in the NKCC1 N-terminal domain
[23]. Phosphorylation of NKCC1 is mediated by at least three
members of a novel family of unusual kinases that lack a key lysine
in their catalytic domain, the WNK kinases (With No K-lysine)
[24,25]. These kinases have been implicated in the pathogenesis of
hypertension and epilepsy [26,27]. Of these, WNK3 is the most
abundantly expressed in the brain [28]. Interestingly, WNK1 is a
substrate for Akt-mediated phosphorylation [29]. Hence, it is
possible that Akt may regulate NKCC1 activity through the
regulation of the WNK kinases. Intracellular signaling pathways,
such as phosphoinositide 3-kinase (PI3K)-Akt, are frequently
altered in GBs [30]. Akt is able to regulate various cellular functions
through phosphorylation of a conserved substrate sequence, and
altered regulationofthispathwaycanlead toaberrantcell behavior,
such as increased proliferation and migration [31–33]. Importantly,
intracellular signaling pathways of promigratory factors such as
epidermal growth factor (EGF) [34–36], and integrin signaling
pathways converge on Akt, modulating cell processes such as cell
cycle, apoptosis, and migration [37]. PI3K, the activator of Akt, is
thought to be critical in mediating both chemotactic and random
cell migration [38]. Therefore, the regulation of NKCC1 by the
interaction between Akt signaling and WNK kinases may be
important in determining the invasive properties of GB cells.
To further our understanding of the role of NKCC1 in GB cell
migration and invasion, we investigated (1) whether the expression
of NKCC1 in human tumors correlates with tumor grade, (2)
whether NKCC1 affects cell contractility and migration, (3)
whether NKCC1 can have an effect on the interaction between
the cells and the cells’ adhesion substratum, and (4) whether a
signaling mechanism involved in the regulation of NKCC1 by
promigratory factors exists in GB cells. We found that NKCC1
expression indeed correlates with in vivo glioma aggressiveness
and that the transporter activity modulates migration speed and
invasiveness of cells derived from various human GBs. Further-
more, we show that NKCC1 expression affects GB cell traction
forces, possibly by regulating focal adhesion dynamics. Moreover,
the regulation of NKCC and KCC transport by WNK3 may
determine the invasive behavior of GB cells. Additionally, we show
evidence of NKCC1 phosphorylation regulation by Akt through
WNK3 phosphorylation upon stimulation with a promigratory
factor, EGF. This suggests an important link between the acti-
vation of WNK3 by Akt as well as changes in the activity of ion
transport systems in glioma cells. Taken together, these findings
strongly suggest that ion transport regulation might be integrated
into the control of glioma cell invasiveness in a complex fashion
that extends beyond regulation of cell volume and involves the
interplay between cell adhesion and growth factor signaling.
The understanding of these complex interactions may assist in the
design of novel therapeutic strategies.
Results
NKCC1 Is Essential for Glioma Cell Invasion
Prior data implicating NKCC1 in GB invasiveness were based
on established, model GB cell lines, rather than primary cells or
tissues. We therefore first evaluated and characterized whether
primary cells isolated from human GB indeed supported the role
of NKCC1 in invasiveness as suggested previously [13]. We
assayed invasiveness using the transwell invasion assay in the
presence or absence of the NKCC1 inhibitor bumetanide [39].
Inhibition of NKCC1 transport in various primary human glioma
cells exposed to 25 and 50 mM of bumetanide led to a dose-
dependent decrease in the number of invasive cells (Figure 1A and
Figure S1A). Significant inhibition of invasion was seen in GB cells
tested at a concentration of 50 mM (Figure S1B), a concentration
at which bumetanide does not exhibit considerable non-specific
effects on other cation-chloride transporters [40,41]. To further
examine whether the effect of bumetanide on cell invasion is due
to inhibition of NKCC1, we performed stable knockdown of
NKCC1 using lentiviral particles carrying NKCC1 shRNA.
Knockdown of NKCC1 in GB cells (NS561, NS567, NS501,
and NS318) was successfully established in 4 GB cell lines and the
efficiency of knockdown was assessed by immunoblot of whole cell
lysates of these GB cells (Figure S1C). We confirmed that, as
previously shown by Haas and colleagues [13], knockdown of
NKCC1 significantly reduced the invasiveness of all these cells
(Figures 1B, S1D). Taken together, these data suggest that
NKCC1 may indeed play a role in invasiveness of primary GB
cells, supporting prior results [13] obtained in non-primary cell
cultures.
Since NKCC and KCC transporters work in a concerted
inverse manner to regulate intracellular volume and intracellular
chloride concentration ([Cl
2]i) [42], we tested whether inhibition
of KCC transport, an important Cl
2 extrusion mechanism, might
mimic NKCC1 overexpression and lead to increased invasion. To
Author Summary
Treatment of many cancers has been hampered by the
invasive ability of tumor cells. A notable example is brain
cancer, which is incurable due to its invasiveness and
resulting high tumor recurrence after surgical resection.
Here, we analyze further the function of NKCC1, an ion
transporter that is known to regulate cell volume and
intracellular chloride concentration, and to play an
important role in brain tumor cell invasion. Our findings
suggest that in addition to its conventional function as an
ion transporter, NKCC1 may also interact with the
cytoskeleton and affect brain tumor cell migration by
acting as an anchor that transduces contractile forces from
the plasma membrane to the extracellular matrix en route
to cell migration. Moreover, we show that regulation of
NKCC1 by a family of unconventional enzymes, the WNK
kinases, is an important factor that affects the activity of
NKCC1 and may determine the invasive ability of brain
tumor cells. We postulate that NKCC1 has multiple
functions in brain tumor cell migration and that together
with its regulatory enzymes may be therapeutic targets in
the treatment of brain tumors or other types of cancer,
given the wide expression of these proteins throughout
the body.
Novel Role of NKCC1 in Brain Tumor Dispersal
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in the presence of DIOA (R(+)-Butylindazone), a potent K
+-Cl
2
transport inhibitor that has no effect on NKCC transport activity.
Consistent with this hypothesis, inhibition of KCC transport with
DIOA resulted in increased cell invasion. This effect was sta-
tistically significant in two of the four cell lines tested (NS221 and
NS318) (Figure 1C). DIOA is a non-specific inhibitor of KCC co-
transporters, which may be the cause of a heterogeneous effect on
GB cells observed. To avoid this confounding result we induced
the genetic knockdown of KCC4 (Figure S1E), a KCC family
member implicated in cervical and ovarian cancer invasiveness
[43]. KCC4 had similar expression levels in the cell lines used for
the experiments (Figure 2D). Knockdown of KCC4 in NS318
showed a significant increase in the number of invading cells
(Figure 1D). These data suggest that KCC transport inhibition
could lead to an increase in [Cl
2]i promoting invasive behavior of
GB cells.
NKCC1 Silencing Leads to Decreased GB Stem Cell
Invasiveness In Vivo
It is thought that GB tumor stem cells may be the core
component of the invasive cell population [44]. Therefore, in
addition to invasiveness of primary GB cells in vitro, we explored
the role of NKCC1 in the invasion of primary brain tumor stem
cells (BTSC) in vivo. Tumor area and area of invasion in the
corpus callosum were then quantified to evaluate differences in
tumor size and invasive ability of BTSCs carrying the control
shRNA as well as BTSCs carrying NKCC1 shRNA. We found
that tumors generated after the implantation of BTSCs with
control shRNA were significantly smaller than tumors generated
with the NKCC1 shRNA harboring BTSC line (Figure 1E).
Consistent with previous results by Haas and colleagues using
commercial GB cell lines [13], the invaded area in the corpus
callosum of mice that were implanted with BTSCs carrying the
control shRNA was significantly larger than that of mice im-
planted with BTSCs carrying NKCC1 shRNA (Figure 1F).
NKCC1 knockdown did not affect the proliferative potential of
the BTSCs injected in vivo (Figure S2). These results suggest that
NKCC1 may be an important determinant of primary and GB
stem cell invasiveness, in congruence with prior suggestions based
on commercial GB cell lines [13].
NKCC1 Protein Expression in Human Gliomas Correlates
with Tumor Grade
To evaluate the potential clinical importance of NKCC1 in
glioma invasion in vivo, we characterized NKCC1 expression in a
large array of glioma tissue samples using a tissue microarray
(TMA) containing several tumors of different grades ranging from
World Health Organization (WHO) Grade II to WHO Grade IV
(Table S1). The results revealed that NKCC1 protein expression
was significantly higher in GB and anaplastic astrocytoma (AA)
tissue samples compared with expression in Grade II astrocytomas
and normal brain (Figure 2A and 2B). Epithelial tissues included in
the TMA were used as positive controls (intestinal mucosa and
tissue from the distal collecting duct in the kidney) (Figure 2B).
As a corollary to this analysis and a complement to the results in
Figure 1, we characterized the expression levels of NKCC1
protein in multiple primary human GB cells and found that all cell
lines tested showed substantial expression of NKCC1 (Figure 2C).
The data obtained from this set of samples showed that NKCC1
protein expression indeed correlates with glioma grade, in that
tissues from GB and AA expressed higher NKCC1 protein levels
than low-grade astrocytomas and normal brain. This correlation
between NKCC1 expression with glioma grade suggests that
NKCC1 may contribute to the increased invasiveness of high-
grade tumors.
Figure 2. NKCC1 is highly expressed in GB tissue samples and primary human GB cells. (A) Quantification of NKCC1 immunoreactivity in a
tissue microarray (TMA) containing samples of multiple glial tumors of different grades. The quantification was done using FRIDA software [100]. Red
lines represent mean immunoreactivity levels. (B) Representative images of NKCC1 immunohistochemistry in tissue cores from the TMA including
glial tumors of different grades, normal brain, and epithelial tissues, which express NKCC1 in the apical surface of epithelial cells as a positive control.
(C) Immunoblot showing NKCC1 expression in multiple glioma cell lines. Information on the number of samples, age, and gender of the patient of
origin of each tumor type can be found in Tables S1 and S2. (D) KCC4 expression by real-time PCR in different glioma cell lines. * p value,0.001.
doi:10.1371/journal.pbio.1001320.g002
Figure 1. NKCC1 activity is necessary for GB cell invasion in vitro and its inhibition leads to formation of less invasive tumors in
vivo. Quantification of transwell invasion assays of primary-cultured GB cells exposed to increasing doses of the NKCC1 inhibitor bumetanide (A) or
transduced with NKCC1 shRNA (B); exposed to 10 mM of the KCC inhibitor DIOA (C) or stably transduced with KCC4 shRNA (D). Insets show schematic
representation of the experimental design in (A) and (D). (E–F) Orhtotopic in vivo tumors formed by NKCC1shRNA cells were significantly larger and
less invasive than control cells. Inset shows NKCC1 knockdown by protein expression. (G) Representative images of DAPI-stained coronal sections of
mouse brains, after the implantation of control shRNA (left panel) or NKCC1 shRNA (right panel) cells. (G9) Confocal images of human-specific Nestin
positive cells migrating across the corpus callosum at the area in the dotted square in (G). These results suggest that NKCC1 expression is necessary
for efficient GB cell migration in vivo. Scale bars, 500 mm in low magnification panels and 20 mm in high confocal images panels. Bars represent mean
6 SEM. * p value,0.05; ** p,0.005.
doi:10.1371/journal.pbio.1001320.g001
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Migration on Nanopatterned Surfaces
Our results so far strongly suggest that NKCC1 may indeed be
an important determinant of GB cell invasion. While all prior
analyses attempted to link the role of NKCC1 in cell migration
to its role as a cell volume regulator [11,13,14,45], we examined
whether NKCC1 plays an essential role in the regulation of
polarization of cell morphology and migration of GB cells. We
were particularly interested in whether NKCC1 might affect cell
migration and how this migratory behavior may depend on the
mechanical cues mimicking the extracellular matrix components.
In this study we employed nanoscale grooves to analyze the
migratory behavior of glioma cells. Our substrate mimics ECM
features, such as myelinated fiber tracts, upon which brain cancer
cells have been shown to migrate [46,47]. This model offers the
advantage of allowing biased cell migration along the nano-ridges
of the textured surface that can be quantified in terms of cell speed
and migration (Figure S3A–C). We found a significant reduction
in the cell migration speed of human primary GB cells stably
transduced with NKCC1 shRNA (Figure 3A–B). Similarly, a
significant decrease in migration speed was observed when GB
cells were treated with bumetanide (Figure S3D). Migration
directionality was quantified by measuring the ratio of cell
movements parallel to the ridges on the pattern versus those that
were perpendicular to the pattern. This metric tended to correlate
with the speed of migration, showing significant decreases in
directionality for cells expressing NKCC1 shRNA (Figure 3C–D).
Overall, GB cells stably transduced with NKCC1 shRNA
displayed a lower speed of migration and showed more random
migration as demonstrated by the decrease in directionality.
NKCC1 Deficiency Increases the Size of Focal Adhesions
and Decreases Net Contractile Moments in GB Cells
The cell migration data indicated that NKCC1 can directly or
indirectly affect cell motility, but the mechanism of how an ion
transporter can be involved in this process is not immediately
apparent. It is therefore of interest to note that at least some ion
transporters have been reported to associate with the ERM com-
plex to anchor actin to the plasma membrane, affecting cell
migration [16,19]. The ERM complex proteins bind to clusters of
positive amino acids such as lysine (K) and arginine (R) in proteins
that are known to bind ERM proteins and to serve as anchors for
the actin cytoskeleton such as CD44, CD43, and ICAM-2 [20].
Also, NHE1, a Na
+-H
+ exchanger, acts as an anchor for the
cytoskeleton in migrating cells, through the interaction with ERM
proteins [16]. Based on these data, we studied the sequence of the
juxtamembrane carboxy-terminus domain of human NKCC1 and
found clusters of positively charged amino acids identical to those
found in other ERM binding proteins. These clusters of positive
amino acids are conserved in the human, mouse, and rat NKCC1
sequences (Figure 4A). These amino acids may be important in the
interaction between ERM proteins and NKCC1 and may be
similar to other ERM-integral membrane protein binding [20].
To assess the possibility that NKCC1 may affect GB cell mi-
gration through a mechanism other than cell volume regulation,
we compared the size of focal adhesions formed by NKCC1
knockdown cells and cells transduced with the control shRNA.
Focal adhesions were stained with an antibody against vinculin
and paxillin, cytoskeletal proteins that are part of focal adhesions
that also regulate mechanical coupling of the cytoskeleton to the
extracellular matrix (ECM). We observed small, thin, and elon-
gated focal adhesions primarily in the extending processes in
control virus shRNA cells, whereas in NKCC1 shRNA cells,
focal adhesions were much larger (Figure 4B–C and Figure S4),
indicative of focal adhesion maturation [22,48]. The area of focal
adhesions was significantly larger in NKCC1 shRNA cells when
compared to control virus cells (Figure 4D). The increased focal
adhesion area was also seen when we used paclitaxel (a drug that
stabilizes microtubules dynamics and disrupts focal adhesion
formation) as a positive control for this experiment [49]. These
results suggest that NKCC1 expression not only regulates cell
volume but may also be important in modulating focal adhesion
dynamics and maturation.
Cells exert traction forces on their environment during mi-
gration and invasion in response to different mechanical and
chemical cues in the extracellular matrix. These forces are applied
through points of cell adhesion via focal adhesion-mediated
integrin-ECM connections [21,22]. To evaluate whether the
increase in size of focal adhesions after NKCC1 depletion had a
functional effect on the generation of contractile forces by GB
cells, we quantified cell traction forces exerted by adherent living
GB cells (control virus versus NKCC1 shRNA). We found that
NKCC1-deficient cells exerted significantly lower cell traction
forces than control virus cells (Figure 5A–B). Compared to control
virus cells, NKCC1 shRNA cells exhibited approximately a 40%
decrease (NS501, 44% decrease; NS561, 37% decrease; p,0.002,
nested ANOVA) in net contractile moments, which is a scalar
measure of cell contractile strength (Figure 5C–D, Figure S5). No
within-group differences existed between both tested cell lines.
To further support the interaction of NKCC1 and ERM
proteins, we immunoprecipated endogenously expressed NKCC1
and probed the immunoprecipated lysate with an antibody against
Ezrin. We found that endogenous Ezrin associates with immuno-
precipitated NKCC1. These results strongly suggest that in primary
human GB cells, Ezrin is an NKCC1 binding partner. As expected,
actin, a binding partner of Ezrin, also co-immunoprecipitated with
NKCC1 (Figure 6A). We also performed the reverse experiment
where Ezrin was immunoprecipitated and then probed for NKCC1
on the immunblot. In multiple primary human GB cell lines, we
found that after performing immunoprecipitationof Ezrin, NKCC1
Figure 3. NKCC1 activity is necessary for GB cell migration on a
nanopatterned substrate. Quantification of migration speed (A–B)
and directionality (C–D) of two different GB cell lines stably transduced
with NKCC1 shRNA. NKCC1 shRNA-transduced cells show a decreased
migration speed and directionality when compared to control virus-
transduced cells. Bars represent mean 6 S.E.M. * p value,0.05; ** p
value,0.001. Scale bar represents 50 mm.
doi:10.1371/journal.pbio.1001320.g003
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immunoprecipitated.
To assess whether the association of NKCC1 and Ezrin is
important for the generation of cell traction forces, we mutated the
two clusters of basic amino acids found in the juxtamembranous
domain of NKCC1 (putative Ezrin-binding sites) and measured
the functional consequences in GB cells. We found that the net
contractile movements of cells expressing the Ezrin-binding null
NKCC1 were significantly lower than cells expressing wild type-
NKCC1 (Figure 6C). Furthermore, cells expressing the Ezrin-
binding null-NKCC1 had a lower projected cell area than cells
expressing wild-type NKCC1 (Figure 6D).
Thus, the absence of NKCC1 expression may lead to the for-
mation of more mature focal adhesions. In turn, these mature
focal adhersions may further enhance the adhesion of cells to the
substratum, which decreaces the migration speed of NKCC1
shRNA cells, as observed above. Mature focal adhesions do not
participate in the generation of contractile forces in migrating cells;
rather, they participate in anchoring cells to the substrate [21]. On
the other hand, nascent adhesions apply forces to the substratum
to drive cell movement [21]. Hence, our results suggest that
NKCC1 affects cell-ECM interactions by stimulating higher
traction force generation and lower substratum adhesion, thus
enhancing cell motility in a synergistic fashion.
NKCC1 Is Expressed at the Distal Edge of Extending
Processes of Primary Human GB Cells
The pronounced effect of NKCC1 expression on focal adhesion
formation and cell migration suggests the importance of its partial
intracellular localization. We initially approached this issue by
performing immunocytochemistry experiments on multiple GB
cells. We found that all GB cells had a polarized subcellular
expression of NKCC1. In cells that appeared to have a more
stationary phenotype with multiple projections, the expression of
NKCC1 was primarily correlated with these projections (Figure 7A
and Figure S6). Specifically, NKCC1 was localized either to the
apparent leading edge of a moving cell or to its rear, frequently in
a mutually exclusive pattern (Figure 7B and Figure S6). Expression
of NKCC1-EGFP fusion protein in GB cells supported that
NKCC1-EGFP expression was mainly localized to the plasma
membrane of the extending processes confirming the results
obtained by immunofluorescence (Figure 7B, Figure S7, and
Video S1 and Video S2). In cells spreading on nano-structured
substrata, NKCC1-EGFP localization oscillated between the two
transiently existing edges, before a prominent single edge was
formed. Furthermore, when using immunocytochemistry, we
examined the sub-cellular localization of WNK3, a serine/
threonine kinase that regulates the transport activity of NKCC1
through phosphorylation [26,27,50]. We observed partial co-
localization of WNK3 immunoreactivity with NKCC1 immuno-
reactivity in the edges of extending processes (Figure 7A and
Figure S6). These findings suggest that the cellular localization
of NKCC1 is spatially heterogeneous during GB cell migration.
Although the localization patterns were diverse in different cell
states, the overall pattern that emerged from this analysis was that
NKCC1 is associated with extending processes of the cell. This
finding correlates with the suggestion that NKCC1 is important in
the formation of new focal adhesions and controlling existing focal
adhesions and active cytoskeletal components.
NKCC1 Is Activated by EGF Through Akt-Mediated WNK3
Phosphorylation
The aforementioned data suggest that NKCC1 transport activity is
important for glioma cell migration and invasion, at least in part
through direct regulation of the cytoskeletal and ECM-cell adhesion
dependent processes. NKCC1 transport activity is known to be
regulated through phosphorylation and de-phosphorylation events
mediated by members of the novel serine/threonine kinase family
WNKs [26]. NKCC transport is activated by stimulation with EGF in
corneal epithelial cells [51]. It is well established that EGF promotes
astrocytic [34] and glioma cell migration [36,52,53]. Thus, we
examined the effect of EGF on the phosphorylation of NKCC1 as an
indication of NKCC1-activation using an NKCC1 phospho-specific
antibody [23]. After stimulating glioma cells with EGF, NKCC1
phosphorylation increased in a time-dependent and dose-dependent
manner in NS318 and NS567 cells (Figure 8A). To gain insight into
the regulation of phosphorylation of NKCC1 in an unbiased cellular
system, we stimulated HEK-293 cells with EGF in the presence or
absence of wortmannin (WM), a PI3K inhibitor. After exposure of
HEK-293 cells to EGF, NKCC1 phosphorylation increased signif-
i c a n t l y .H o w e v e r ,i nt h ep r e s e n c eo fW M ,E G F - i n d u c e dN K C C 1
phosphorylation was blocked (Figure 8B). These findings together
demonstrate that the EGF-induced increase in phosphorylation of
NKCC1 requires activation of the PI3K-Akt pathway.
The activity of cation-chloride cotransporters is regulated in a
coordinated manner by the novel family of serine-threonine kinases
WNK [50]. WNK3 promotes phosphorylation and activation of
NKCC1 transporters while promoting phosphorylation and inac-
tivation of KCC transporters [50]. It has also been shown that
WNK1, another member of the WNK family, is phosphorylated
and activated by Akt (protein kinase B) [29,54]. Therefore, we
decided to test if Akt phosphorylates WNK3 after stimulation with
EGF. We immunoprecipitated total WNK3 from HEK-293 cells
exposed to serum-free media, and we stimulated with EGF, or EGF
in the presence of the PI3K inhibitor WM. Samples were im-
munoblotted with an antibody that recognizes phosphorylated Akt
Figure 4. NKCC1 knockdown increases the size of focal adhesions in primary human GB cell lines. Nascent focal adhesions have a
smaller area and are primarily responsible for generating traction and participate in generating contractile forces that allow cells to move. Mature
focal adhesions have a larger area and are responsible for remodeling the extracellular matrix during migration. Primary human GB cells
immunostained for focal adhesion proteins vinculin and paxillin. (A) Left panel, schematic representation of NKCC1, CD44, and NHE1 showing the
localization of putative ezrin-radixin-moesin binding domains (red boxes) in the juxtamembranous intracellular domains of these proteins. Right
panel, alignment of the protein sequences of NKCC1 of human (NP_001037), mouse (NP_033220), and rat (NP_113986) with the sequence of CD44
(NP_000601) and NHE1 (NP_003038), which have been shown to bind ezrin-radixin-moesin proteins to anchor the actin cytoskeleton to the plasma
membrane. In these protein sequences, the positive amino acids such as lysine (K) and arginine (R) are highlighted in red; groups of three positive
amino acids are underlined in blue and groups of two positive amino acids are underlined in green. (B–C) NS 318 control shRNA (left panel), NKCC1
shRNA (middle panel), and wild-type treated with 5 mM paclitaxel (right panel) stained with an anti-vinculin antibody (B) and anti-paxillin antibody (C)
to visualize focal adhesions (lower panels in B and C show an amplification of areas within the squares). (D) Bar chart of the quantification of focal
adhesion area stained with vinculin (left panel) and paxillin (right panel) antibodies. Quantification of vinculin staining NS318 control shRNA n=23
cells, NS 318 NKCC1 shRNA n=26 cells, NS 318 control shRNA+paclitaxel n=22 cells, NS 501 control shRNA n=20 cells, NS 501 NKCC1 shRNA n=20
cells, and NS 501 control shRNA+paclitaxel n=10 cells. Quantification of paxillin staining NS 318 control shRNA n=21 cells, NS 318 NKCC1 shRNA
n=15 cells, NS 318 control shRNA+paclitaxel n=21 cells, NS 501 control shRNA n=12 cells, NS 501 NKCC1 shRNA n=24 cells, and NS 501 control
shRNA+paclitaxel n=10 cells. * p value,0.05; ** p value,0.01. Scale bars represent 50 mm.
doi:10.1371/journal.pbio.1001320.g004
Novel Role of NKCC1 in Brain Tumor Dispersal
PLoS Biology | www.plosbiology.org 7 May 2012 | Volume 10 | Issue 5 | e1001320substrates (aPAS antibody) (Figure 8C). Data obtained from this
experiment showed a basal phosphorylation level of WNK3, which
increases with exposure to EGF. This increase in phosphorylation is
repressed by inhibition of PI3K with WM, suggesting that Akt
phosphorylates WNK3. The same samples were immunoblotted
againstphosphorylatedAkt,andasexpected,wefoundthatWMalso
inhibited the phosphorylation of Akt (Figure 8D). In silico analysis of
the protein sequence of WNK3 revealed that two putative Akt
phosphorylation motifs are present and are conserved in available
WNK3 protein sequences of the human and rat, as previously found
in WNK1 (Figure 8E) [54]. These findings indicate that NKCC1
may be activated by factors that stimulate migration of astrocytic or
glioma cells, such as EGF via kinases of the WNK family, a family of
kinases that have been shown to regulate the transport activity of
multiple members of the SLC12A family of transporters.
Discussion
The nearly universal recurrence of GB after surgical resection is
largely due to invasion of glioma cells into healthy brain tissue and
Figure 5. NKCC1 knockdown decreases the net contractile moment and projected area in primary human GB cell lines. (A and B)
Representative traction maps of GB cells stably expressing control shRNA or NKCC1 shRNA, respectively. The white line shows the cell boundary.
Colors show the magnitude of the tractions in Pascal (Pa). Arrows show the direction and relative magnitude of the tractions. Scale bars represent
50 mm. Inset, phase contrast images of the respective cells on the elastic gel. Computed net contractile moment of GB cells expressing control shRNA
or NKCC1 shRNA in (C), NS 561 (control shRNA n=15 cells, NKCC1 shRNA n=14 cells, p=0.024) and (D) NS 501 (control shRNA n=13 cells, NKCC1
shRNA n=12 cells, p=0.005). Net contractile moment is expressed in pico-Newton meter (pNm). Measurement of the projected cell area in mm
2 of (E)
NS 561 (control shRNA versus NKCC1 shRNA, p=0.01) and (F) NS 501 (control shRNA versus NKCC1 shRNA, p=0.001). Data are presented as
geometric mean 6 SEM in log transformation.
doi:10.1371/journal.pbio.1001320.g005
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survival. In this study, we tested the hypothesis that NKCC1
expression and transport activity are crucial elements of cell mi-
gration and invasion in primary human GB cell lines. Here we
provide evidence for the participation of NKCC1 in the migration
and invasion of primary human glioma cells, highlighting its
possible role in anchoring the actin cytoskeleton to the plasma
membrane. Additionally, through this anchoring, NKCC1 medi-
ates transduction of the cellular contractile forces to focal adhesions
that interact with the extracellular matrix. These in vitro findings
were confirmed functionally in an in vivo model using primary
human BTSCs, where their invasion was decreased significantly
after NKCC1 knockdown. Given these findings, NKCC1 inhibition
could potentially be used in the clinic to improve glioblastoma
treatment, given that Bumetanide (a commonly used diuretic, FDA-
approved) decreases the invasive potential of glioma cells in vivo
[13]. This could potentially improve surgical resection of the tumor
mass, as tumor cells lacking NKCC1 activity would form less
invasive tumors.
Our work shows that NKCC1 protein expression in multiple
glioma samples is higher in high-grade gliomas such as GB and
anaplastic astrocytomas. Inhibition of NKCC1 transport pharma-
cologically, as well as genetic inhibition of NKCC1 expression,
decreases invasion of multiple primary human GB cell lines. These
results are in accordance with previous findings using commercial
human glioma cell lines [13]. Our data further indicate that
migration speed of GB cell lines in a 2-D nanopatterned substrate
is decreased by pharmacological inhibition and by shRNA-based
silencing of NKCC1 expression. Interestingly, pharmacological
and genetic inhibition of the K
+-Cl
2 cotransporters leads to a
more invasive behavior of GB cells in vitro. Moreover, our results
suggest that NKCC1 may affect the morphology of focal adhe-
sions, perhaps due to a putative ERM binding motif in the
cytoplasmic domain of NKCC1. We also found that NKCC1 is
located at the extending processes of GB cells and that NKCC1
polarization may precede migration towards the direction of this
pole. Furthermore, exposure of GB cells to EGF, a factor that
promotes migration and invasion of normal and tumor cells [34–
36,55,56], induces phosphorylation (activation) of NKCC1
through PI3K-Akt-WNK3 pathway.
The concerted action of local anchoring of the actin micro-
filaments to the plasma membrane and volume regulation may be
important for the polarization of cells during migration. Coupling
the actin cytoskeleton to the plasma membrane is essential for the
regulation of cell morphology and migration [6]. Our immuno-
cytochemistry and live cell imaging experiments using a GFP-
NKCC1 fusion protein demonstrate that NKCC1 is localized to
the extending processes of migrating GB cells. During the mi-
gratory process, cells acquire a polarized morphology where actin,
integrin receptors, and ion transporters among other proteins,
become asymmetrically distributed in the cell. Some examples of
ion transporters that show a polarized localization to the leading
edge of the cell include NHE1 and AE2 [9,16,17], which also have
K
+ channels that are polarized to the rear end of the cell [57].
Ezrin-radixin-moesin (ERM) proteins bind actin filaments and
anchor them to integral plasma membrane proteins. Some of these
integral membrane proteins include NHE1, CD44, and intercel-
lular cell adhesion molecule 2, which have ERM binding motifs
Figure 6. NKCC1-Ezrin association affects net contractile moments and projected cell area. (A) Immunoprecipitation of NKCC1 in two GB
cell lines shows that Ezrin and actin are associated with NKCC1. (B) Immunoprecipitation of Ezrin pulls down NKCC1 in several GB cell lines. (C) Cells
that overexpress Ezrin-binding null NKCC1 generate lower contractile moments and have lower surface area. Black bars represent the transfected
cells, and white bars represent the untransfected cells. Measured cells in the WT group (n=16 untransfected cells; n=11 transfected cells), and
measured cells in the mutant group (n=17 untransfected cells; n=12 transfected cells). Bars represent mean 6 S.E.M. * p value,0.001.
doi:10.1371/journal.pbio.1001320.g006
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of positive amino acids, such as lysine and arginine residues in
juxtamembranous intracytoplasmic domains of these proteins. By
analyzing the peptide sequence of NKCC1, we found clusters of
lysine and arginine residues in the N-terminal cytoplasmic domain
that are conserved across mammalian species, which may bind
ERM proteins. Indeed, we found that NKCC1 is able to bind to
Ezrin and actin with our co-immunoprecipitation assay. The
generation of advancing membrane protrusions is necessary for
migrating cells to achieve cell translocation. ERM protein binding
to NHE1 is necessary during migration to promote extension of
advancing processes to anchor the cytoskeleton [16,17]. Our
results show that NKCC1 is polarized to the extending processes
of migrating glioma cells; therefore, it is likely that NKCC1 is
necessary during migration to anchor the cytoskeleton, aiding in
the extension of lamellipodia, and mediate local volume changes at
the same time [14].
NKCC1 expression may be an important determinant of the
response of migrating cells to external physical cues. The ex-
tracellular matrix surrounding cells presents topographical features
ranging from nanometers (nm) to microns (mm) and affects cell
behavior. For example, collagen fibrils form with diameters from
20–200 nm and influence cell polarity and migration through
‘‘contact guidance’’ [58–65]. Recent studies have employed more
intricate substrates presenting nanoscale features (e.g., grooves,
ridges, bumps, and pillars) to more closely model the cellular
microenvironment [66–68]. In this study, we have employed
nanoscale features mimicking the ECM found in the brain. These
features include myelinated fiber tracts, upon which brain
cancer cells have been shown to migrate [47]. It is known that
cell migration is governed by many molecular processes, including
attachment to the cell substrate. Our nanopattern provides a quasi-
3-D platform that can examine these interactions with ECM by
examining speed, direction, and morphologies of migrating cells.
While cells move in 2-D, they respond to topographical cues from
the substrate presented in 3-D [46,69].
By examining cell migration after genetic changes to NKCC1
expression, we sought changes that might inhibit the overall motility
of glioma cells. Our observed changes in migratory behavior upon
simulated ECM suggests that these cells will be less migratory and
invasive, eventually leading to improved medical outcomes. These
changes in migratory behavior were further supported by our ex-
periments employing more classical techniques (e.g., transwell).
It has been shown that formation of actin stress fibers precedes
the formation of nascent focal adhesions in the lamellipodium of
fibroblasts [70]. However, stress fiber formation depends on the
anchorage of actin bundles to the plasma membrane, which has
been shown in the interaction of NHE1 with ERM proteins [16].
Nascent adhesions are present at the front of the cell and exert
traction forces that lead to cell repositioning [21]. As focal ad-
hesions increase in size, they mature and the traction forces that
they exert decrease considerably [21]. In migration studies of cells
that do not express focal adhesion kinase (FAK), a major regulator
of focal adhesion turnover, it was shown that these cells possess
larger focal adhesions and display lower cell spreading [71,72]. In
fact, these observations were also seen in GB cells when NKCC1 is
knocked down; NKCC1 knockdown cells display larger focal
adhesions and smaller projected cell area than control shRNA
cells. These changes in focal adhesion size were accompanied by a
decrease in the generation of contractile forces by GB cells. These
findings suggest that the localized distribution of NKCC1 to the
extending processes plays a role in the modulation of focal ad-
hesion turnover and generation of nascent focal adhesion to
maintain cell contractility and traction for efficient migration.
Cell volume changes are expected in migrating cells since al-
terations in shape during extension and retraction occur through-
out migration. Multiple ion transport mechanisms are responsible
for regulating and maintaining cellular volume in response to
changes in extracellular osmolarity and during cell migration [5];
in addition, ion gradients and local volume changes have been
described in migrating cells [73,74]. These mechanisms include
ion transporters such as NKCC1, NHE1, KCC transporters, and
also ion channels. For instance, neutrophils undergo an increase in
intracellular volume in response to the chemotactic factor N-
formylmethionyl-leucyl-phenylalanine; this increase in cell volume
and increased migration is blunted by NHE1 transport inhibitors
and by exposure to hyperosmolar solutions, suggesting that
NHE1-mediated volume increase is necessary for neutrophil
migration [7,75]. Na
+-K
+-Cl
2 transport inhibition has also shown
to decrease Madin-Darby canine kidney cell migration [74]. Our
results are in accordance with the findings discussed above where
inhibition of NKCC transport decreases migration. We also show
that NKCC1 knockdown decreases GB cell migration, confirming
the effects of pharmacologic inhibitors. Pharmacological inhibitors
and shRNA-based approaches may have off-target effects, but the
fact that the effect of both on GB cell migration is the same
confirms that the results seen by manipulating NKCC1 expres-
sion/transport are consistent.
EGFR activation promotes migration of normal neuroblasts,
astrocytes, and glioma cells [34,53,76–78]. EGF signaling affects
migration through diverse mechanisms, such as actin polimeriza-
tion [79,80], focal adhesion kinase regulation [81–83], and matrix
metalloproteinase expression [84]. EGF mediates its effects on cell
migration and proliferation through activation of its receptor-
tyrosine kinase and the various downstream signaling pathways,
which include the PI3K-Akt pathway. NKCC1 phosphorylation
by WNK3 after activation of the PI3K-Akt pathway supports the
hypothesis that NKCC1 activity is necessary for GB cell migration.
Furthermore, WNK3 activation after EGF stimulation suggests
that phosphorylation and activation of NKCC1 and phosphory-
lation and inhibition of KCC transporters may result in GB cell
migration. Therefore it seems this balance between these opposing
transport activities is important in the determination of GB cell
invasion.
The PI3K-Akt signaling pathway, among many other cell
functions, is central in the control of cell motility and polarization.
PI3K is activated by receptor tyrosine kinases and Ras [85]. It
modulates these functions by bringing diverse proteins that are
able to bind phosphatidyl-inositol triphosphate (PIP3) close to the
membrane. A notable example of the proteins that are recruited to
the membrane is Akt, which is activated after binding to PIP3
and phosphorylated by 39-phosphoinositide-dependent kinase 1
Figure 7. NKCC1 localizes to the extending processes of migrating cells with directional polarization. (A) Images of NS 253 cells
immunostained with T4 antibody (red, left panel), WNK3 antibody (green, center panel), and DAPI (blue). The right panel shows co-localization of
NKCC1 and WNK3 immunoreactivity. Below, high magnification images of the area in the dotted boxes are presented for more detail. Areas of
colocalization are pointed out using arrowheads. Scale bars represent 50 mm. (B) Images of NS 561 cells expressing NKCC1-GFP protein migrating on
a nanopatterned substrate shows localization to the advancing edge of extending processes in migrating cells at time-point 0 min (left panel), 2 h
(center left panel), 3 h (center right panel), and 4 h (right panel).
doi:10.1371/journal.pbio.1001320.g007
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phosphorylation. (A) Treatment of GB cell lines NS 318 and NS 567 with EGF (30 ng/ml) stimulates phosphorylation of NKCC1. Exposure of cells to
EGF (30 ng/ml) for 10, 30, and 60 min show a time-dependent course of NKCC1 phosphorylation. Also, exposure of NS 567 to 60 ng/ml of EGF shows
higher levels of phosphorylation than phosphorylation levels at the same time point at 30 ng/ml showing a dose-dependent effect. A line plot is
presented with the quantification of the ratio of p-NKCC1/NKCC1. (B) Activation of PI3K is necessary for phosphorylation of NKCC1 after stimulation of
HEK-293 cells with EGF. HEK-293 cells were serum starved overnight and were incubated with wortmannin (WM) for 30 min prior to stimulation with
EGF for 30 min. Total cell lysate (150 mg) was immunoprecipitated with T4 antibody before immunoblotting with anti-phospho NKCC1 antibody (top
panel) or T4 antibody (bottom panel). (C) Activation of PI3K is necessary for increased phosphorylation of WNK3 after stimulation with 30 ng/ml EGF.
After overnight serum starvation, HEK-293 cells were incubated with WM for 30 min prior to stimulation with EGF for 30 min. Total cell lysate (150 mg)
was immunoprecipitated with WNK3 antibody before immunoblotting with anti-phosphorylated Akt substrate (aPAS) antibody (top panel) or WNK3
(bottom panels). (D) Total cell lysate samples (25 mg) were also resolved by SDS-PAGE and blotted with phospho-Akt (threonine 473, top panel) and
Akt (bottom panel) antibodies to show inhibition of Akt phosphorylation after PI3K inhibition. A line plot is presented with the quantification of the
ratio of p-NKCC1/NKCC1, aPAS/WNK3, and p-Akt/Akt. (E) Akt phosphorylation motif, top panel. Middle panel shows the alignment of the sequences
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edge of the migrating cell membrane [86]. It is well known that
PI3K activation mediates cytoskeletal rearrangements and cell
polarization through the action of the guanine nucleotide exchange
factors (GEFs) [87,88]. Moreover, PI3K modulates actin polymer-
ization and membrane insertion at the leading edge of a cell by
regulating the activity of Arf [89]. Its activation also promotes cell
polarization through Rac regulation [90]. It is still necessary to
assess if the cytoskeletal rearrangements and cell polarization
mediated by PI3K are important in the generation of the partial
distribution of NKCC1 to the extending processes of GB cells.
WNK3 regulates ion transport through phosphorylation: it
phosphorylates and activates NKCC1 and phosphorylates and
inhibits transport of the KCC transporters in a reciprocal manner
[27,50]. Furthermore, Haas et al. have shown that following a
hyperosmotically induced decrease in cell volume, WNK3 may
regulate NKCC1. Also, the reduced expression of WNK3 by
shRNA diminished the ability of glioma cells to migrate in vitro
[91]. Ourresults show that inhibitionofNKCCand KCC transport
result in opposite effects in GB cell migration. Similar to WNK1,
our immunoprecipitation experiments show that EGF induces
phosphorylation of WNK3 through Akt [29,54]. When phosphor-
ylated, WNK3 then phosphorylates NKCC1 and possibly KCC
transporters. This mechanism is similar to the mechanism proposed
for increased excitability of neurons, where WNK3 signaling is
impaired, resulting in GABA-mediated excitation of neurons and
seizure activity [27]. Therefore, it is conceivable that WNK3
activation results in activation of NKCC1 and inhibition of KCC
transport, causing increased migration of GB cells.
In this study, we show that NKCC1 transport expression and
activity are necessary for GB cells to migrate and invade. The
mechanism affecting cell contractility that we report in this article
may be independent from regulation of volume changes and may
be due to regulation of focal adhesion formation and turnover. We
also show that EGF regulates NKCC1 phosphorylation through
an Akt-WNK3 pathway, linking the PI3K-Akt pathway to the
WNK3 kinase. This suggests that WNK3 may have a role in
determining GB cell migratory properties. Furthermore, given that
NKCC1 is ubiquitously expressed, it is possible that it plays a very
similar role in physiological migration such as inflammatory cell
diapedesis or neural precursor migration during development, as
well as in the process of metastasis of other highly aggressive
cancers.
Materials and Methods
Cell Lines
Patient samples of glioma tissues were obtained at the Johns
Hopkins Hospital under the approval of the Institutional Review
Board (IRB). All human brain tumor cell lines were derived from
intraoperative tissue samples from patients treated surgically for
newly diagnosed glioblastoma multiforme without prior treatment
as listed in Table S2. Differentiation potential of cell lines for an in
vivo experiment was evaluated by immunohistochemistry against
GFAP, TuJ1, and NG2 (Figure S9). Detailed culture methodology
has been previously described [92,93].
Generation of NKCC1-shRNA Stable Expressing Cell Lines
VSV-G pseudotyped virus was produced by co-transfecting
293T cells with a shRNA transducing vector and two packaging
vectors: psPAX2 and pMD2.G. The shRNA sequence used was
59-TAG TGC TCT CTA CAT GGC ATG GTT AGA AGC
TCT ATC TAA GGA CCT ACC ACC AAT CCT C-39.
Seventy-two hours after transduction, cells were cultured in the
presence of puromycin for selection of cells expressing the shRNA.
Knockdown was assessed by quantitative PCR (Figure S8) and
immunoblot (inset in Figure 1F and Figure S1C).
Cloning of Full-Length Human NKCC1 cDNA, Site-
Directed Mutagenesis, Subcloning Into Lentiviral Vector,
and Generation of EGFP Fusion Protein
The sequence of human NKCC1 (SLC12A2, accession number
NM001046) was amplified by PCR using gene-specific primers.
The sequence of the primers employed is as follows: sense, 59-
GCG TGC TGC CGG AGA CGT CC-39; antisense, 59- AGT
CAC CAT TCG CCA TTG TGA TGT T-39. The resulting PCR
product was cloned into pCR-XL-TOPO (Invitrogen). The cloned
sequence was verified in its entirety to confirm the absence of
mutations. The EGFP fusion protein was made by cloning the
NKCC1 open reading frame into pcDNA3-EGFP using standard
cloning procedures. All other procedures are listed in Supplemen-
tal Experimental Procedures (Text S1).
Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from primary glioma cell lines using
the RNAeasy kit (Qiagen) and reverse transcribed using the
SuperScript III First-Strand Synthesis System for RT-PCR
(Invitrogen). The target cDNAs were analyzed using SYBR Green
PCR master mix (Applied Biosystems) in a 7300 Real-Time PCR
system (Applied Biosystems). For relative quantification, the results
obtained were compared to the levels of target mRNA expression
present in the control cell line and normalized for GAPDH
expression. Primers are listed in Supplemental Experimental
Procedures (Text S1).
Immunoblotting
NKCC, WNK3, Akt, Ezrin, and actin were detected using
rabbit and mouse primary antibodies. Detection was done with the
appropriate horseradish-peroxidase conjugated secondary anti-
bodies and using the enhanced chemiluminescence reagent (GE
Healthcare Life Sciences). Antibodies are listed in Supplemental
Experimental Procedures (Text S1).
Immunoprecipitation
Cell lysates (150 mg of protein) were incubated with anti-NKCC
antibody (T4 antibody, 1 mg; DSHB) and anti-Ezrin (cell signaling
cat: 3145, 1:100) overnight at 4 uC on a shaking platform. Indirect
immunoprecipitation was done with protein G magnetic beads
(Millipore). Proteins were then eluted and denatured in LDS
protein loading buffer (Invitrogen).
In Vitro Invasion Assay
Fifty thousand cells were plated in the top chamber of a
matrigel-coated membrane (24-well insert; pore size, 8 mm; BD
Biosciences). Cells were plated in medium containing 0.5% of
serum, whereas medium with 2% serum was used as a chemo-
attractant in the lower chamber. After 48 h cells that invaded were
stained and counted for comparison.
of rat and human WNK3 showing conservation of the Akt phosphorylation motif. Bottom panel shows sequence of WNK1, which is phosphorylated
by Akt (bottom panel) [29]. Conserved residues are highlighted in red letters.
doi:10.1371/journal.pbio.1001320.g008
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Migration of glioma cells was quantified using a novel
directional migration assay using nano-ridges/grooves constructed
of transparent poly(urethane acrylate) (PUA), and fabricated using
UV-assisted capillary lithography (see Figure S3A–C) [94].
Nanopattern surfaces were coated with laminin (3 mg/cm2). Cell
migration was quantified using timelapse microscopy (Video S3).
Long-term observation was done on a motorized inverted
microscope (Olympus IX81) equipped with a Cascade 512B II
CCD camera and temperature and gas controlling environmental
chamber. Phase-contrast and epi-fluorescent cell images were
automatically recorded under 106objective (NA=0.30) using the
Slidebook 4.1 (Intelligent Imaging Innovations, Denver, CO) for
15 h at 10–20-min intervals.
Quantitative Analysis of Cell Migration
A custom-made MATLAB script was used to identify cell
boundaries from phase-contrasted images and to measure cell
centroid positions. Average individual cell speed was calculated
from individual cell trajectories and durations of the image
acquisition. Mean squared displacements at various time intervals
were calculated using a previously published method [95].
The spindle shape factor was defined as the ratio of the length of
maximum cell width (maximal axis) to the minimum value of
the cell width in the direction perpendicular to maximum axis,
regardless of the orientation with respect to nanogrooves. For each
condition, over 60 cells were quantified in total.
For quantitative analysis of cell orientation, cells were fixed
and stained for F-actin with phalloidin. The orientation angle of
polarized cell was determined by measuring the acute angle
between the major axis of the cell and the direction of grooves.
More than 100 cells for each group were used to construct the
polarization angle distributions with range 290u and 90u.A
summary of all the migration assays used is presented in Table S3.
Fourier Transform Traction Microscopy (FTTM)
The contractile stress arising at the interface between an
adherent cell and its substratum was measured with traction
microscopy [96]. For each cell analyzed, the traction field was
computed using Fourier transform traction cytometry as described
previously. The computed traction field was used to obtain the net
contractile moment, which is a scalar measure of the cell’s
contractile strength (Figure S5) [97].
Immunofluorescence
Cells were fixed in 4% paraformaldehyde in phosphate-buffered
saline (pH 7.4) for 1 h and blocked with 10% normal donkey
serum in PBS for 1 h. Subsequently, fixed cells were incubated
with primary antibody at 4 uC overnight. The preparation was
then incubated with Alexa Fluor-conjugated secondary antibodies
(Invitrogen) and mounted using Aquamount (VWR). All antibod-
ies and their dilutions are listed in Supplemental Experimental
Procedures (Text S1).
Intracranial GB Cell Injections, Sectioning, and
Histochemistry
All animal protocols were approved by the Johns Hopkins
Animal Care and Use Committee. In vivo invasion and tu-
morigenesis of cells expressing NKCC1 shRNA were assessed in 4-
to 6-wk-old male mice (nude/athymic mice, NCI) using our brain
tumor model as previously described [98]. Mice were sacrificed
8 wk after injection. Brains were fixed using transcardiac per-
fusion, postfixed overnight at 4 uC in 4% formalin, embedded in
OCT compound (Tissue-Tek), and frozen, sectioned, and stained
with an antibody against human nestin (1:500, MAB5326
Millipore). Stained cryosections were used to calculate tumor size
and invasiveness by computer-based morphometrics using Image
J. Please refer to Text S1 for detailed description of the in-
tracranial injection of GB BTSCs.
Assessment of Proliferation
Primary human GB cells expressing the control shRNA and
NKCC1 shRNA were treated with 10 mM 5-ethynyl-20-deoxyur-
idine (EdU). Cells were harvested for detection of EdU incorpora-
tion using Click-iT EdU Flow Cytometry Assay Kits (Invitrogen,
Cat. No. C35002) following the manufacturer’s instructions. The
percentage of cells that incorporated EdU was measured using flow
cytometric detection of EdU. Data were analyzed using Kaluza
software (Beckman Coulter).
Tissue Microarray
A tissue microarray was designed and built according to pre-
viously established methods [99]. Cores were taken from each
tumor mass or control tissue (see Table S1). The tissue that was
included in the cores of the microarray was representative of the
tissue blocks from where the cores were obtained. Analysis and
correction for cell number was done using the FRIDA software
(free web-based tissue microarray analysis software).
Statistical Analysis
Unless otherwise noted, data are presented as mean 6 standard
error of the mean. A t test was used to compare two groups; one-
way analysis of variance (ANOVA) was used in multiple group
comparisons with Bonferroni’s post hoc test. Mann-Whitney rank-
sum test was used to evaluate the statistical significance in
quantification of spindle shape factor where indicated. In order to
satisfy the distributional assumptions associated with the ANOVA,
cell traction force data were first converted to log scale prior to
analyses. For the comparisons between treatments, we used a
nested ANOVA. All analyses were performed in Sigma Plot 9.0
(Systat Software Inc., San Jose, CA) SAS Version 9.2 (SAS
Institute, Cary, NC), and a two-sided p value less than 0.05 was
considered significant.
Supporting Information
Figure S1 NKCC1 activity is necessary for GB cell invasion.
Quantification of transwell invasion assays of NS 221 exposed to
(A) increasing doses of bumetanide. DMSO versus 50 mM. * p
value,0.05. And (B) NS 561, NS 318, NS 221, NS 319, and
NS 243 primary human GB cell lines exposed to 50 mMo f
bumetanide. (C) Immunoblot showing effective knockdown of
NKCC1 in stably transduced NKCC1 shRNA cell lines. (D)
Quantification of transwell invasion assays of NS 567 and NS 501
primary human glioma cell lines stably transduced with NKCC1
shRNA. (E) RT-PCR showing stable knockdown of KCC4 in NS
318. Bars represent mean 6 S.E.M. * p value,0.05. Scale bars
represent 50 mm.
(TIF)
Figure S2 NKCC1 knockdown does not decrease proliferation
of primary human GB cell lines in vitro or in vivo. (A) Proliferation
was measured using Click iT EdU kit (Invitrogen). The fraction of
EdU positive cells was similar in cells expressing control shRNA
and in cells expressing NKCC1 shRNA in all three cell lines
tested: NS 561, NS 501, and NS 318. (B) Quantification of Ki67
positive cells in sections of the in vivo tumors showing no
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sections per mouse) for Control shRNA and n=4 mice (12 sections
per mouse) for NKCC1 shRNA cells; the differences were not
significant. (C) Representative images of Ki67 immunohistochem-
istries and DAPI of the tumor grafts (top panels, Control shRNA;
bottom panels, NKCC1 shRNA). Bar represents 20 mm.
(TIF)
Figure S3 NKCC1 knockdown decreases migration speed and
directionality in primary human GB cell lines. (A) Diagram
representing a raw nanopatterned surface (left). After ECM-coating
(red), cells migrate following the mechanical cues (right). (B)
Representative scanning electron microscopy image of the nanopat-
terned substrate. (C) Representative phase contrast image of GB cells
aligned to a nanopatterned surface. (D) Quantification of cell migration
on a nanopattern surface when cells are exposed to the NKCC1
inhibitor bumetanide. Bars represent mean 6 S.E.M. * p value,0.05.
(TIF)
Figure S4 NKCC1 knockdown increases the size of focal
adhesions in primary human GB cell lines. NS 501 control
shRNA (left panel), NKCC1 shRNA (middle panel), and wild-type
treated with 5 mM paclitaxel (right panel) stained with an anti-
vinculin antibody (A) and anti-paxillin antibody (B) to visualize
focal adhesions.
(TIF)
Figure S5 A detailed description of this technique is given by
Butler and colleagues [97,101]. In brief, cells are plated sparsely
on polyacrylamide elastic gel block coated with collagen type I
(0.2 mg/ml) and allowed to spread and stabilize for 24 h. (A) Phase
contrast image of a single primary human glioma cell adhered to
the elastic gel substrate. For each adherent cell, images of fluo-
rescent microbeads (B), 0.2 mm in diameter (Molecular Probes,
Eugene, OR), embedded near the gel apical surface are taken at
different times; the fluorescent image of the same region of the gel
after detachment of the cell with trypsin is used as the reference
(traction-free) image. The displacement field between a pair of
images is then obtained by identifying the coordinates of the peak
of the cross-correlation function [97,101,102]. From the displace-
ment field (C) and known elastic properties of the gel, the traction
field is calculated using both unconstrained and constrained
Fourier transform traction cytometry [97,101,102]. The computed
traction field is then used to obtain contractile moment, which is a
scalar measure of the cell’s contractile strength that requires no
estimation of cell geometry [97,101]. Here contractile moment is
expressed in pico-Newton meters (pNm).
(TIF)
Figure S6 NKCC1 localizes to the extending processes and
colocalizes with WNK3 immunoreactivity in primary human GB
cells. (A) Images of NS 319 cells immunostained with T4 antibody
(red, left panel), WNK3 antibody (green, center panel), and DAPI
(blue). Merge in the right panel showing co-localization of
NKCC1 and WNK3 immunoreactivity. (B) NKCC1 localizes to
the edge of extending processes in multiple primary human GB
cell lines. Scale bars, 50 mm.
(TIF)
Figure S7 Confocal mages of NS 318 cells transfected with
NKCC1-GFP migrating on a flat surface at (A) 0 min, (B) 12 min,
(C) 20 min, and (D) 36 min. Note localization of NKCC1-GFP in
the extending lamellipodia as demonstrated by the arrowheads.
Scale bars represent 100 mm.
(TIF)
Figure S8 Assessment of NKCC1 knockdown efficiency of five
different shRNA sequences using real-time RT-PCR. Bar chart
showing fold change in mRNA levels of NKCC1 in NS 253
glioma cell line expressing five different shRNA sequences. shRNA
#2 showed the best knockdown efficiency when compared to
control shRNA.
(TIF)
Figure S9 Assessment of differentiation of NS 551 BTSCs into
the three neuronal lineages. Immunostains of NS 551 cells
differentiated against Tuj1 (neuronal marker), GFAP (astrocytic
marker), and NG2 (oligodendroglial marker).
(TIF)
Text S1 Supplemental experimental procedures.
(DOC)
Video S1 NKCC1-EGFP localizes to extending processes of
migrating GB cells on nanopatterned surfaces. NS 318 cells
transfected with NKCC1 GFP were plated on a nanopatterned
surface, and timelapse imaging was obtained showing that
NKCC1-EGFP localizes to the extending processes of migrating
GB cells.
(MOV)
Video S2 NKCC1-EGFP localizes to extending processes of
migrating GB cells on flat surfaces. NS 318 cells transfected with
NKCC1-EGFP were imaged using a spinning disk confocal
microscope that allowed us to obtain better spatial resolution of
the localization. This experiment shows how NKCC1-EGFP
localizes exactly to the membrane of ruffles of extending
lamellipodia.
(AVI)
Video S3 Migration of brain tumor cells on a nanopatterned
surface. NS 318 cells were plated on a nanopatterned surface that
provides cells with nanomechanical cues that attempt to
recapitulate the extracellular matrix. Please note how cells migrate
in a linear fashion in parallel to the nanogrooves. Nanogrooves are
horizontally oriented in this experiment.
(MOV)
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